Showing 2221-2230 of 5771 results for "".
- Oyster Point Pharma Announces Pricing of Initial Public Offeringhttps://modernod.com/news/oyster-point-pharma-announces-pricing-of-initial-public-offering/2477064/Oyster Point Pharma announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $16.00 per share. The shares began trading on The Nasdaq Global Select Market on October 31, 2019 under the symbol “OYST.” All of the shares ar
- Aldeyra Therapeutics Releases Expanded Results from Allergen Chamber Trial and Announces Plans to Initiate the Phase 3 INVIGORATE Trial in Patients with Allergic Conjunctivitishttps://modernod.com/news/aldeyra-therapeutics-releases-expanded-results-from-allergen-chamber-trial-and-announces-plans-to-initiate-the-phase-3-invigorate-trial-in-patients-with-allergic-conjunctivitis/2477060/Aldeyra Therapeutics announced expanded results from the company’s allergen chamber clinical methods trial of topical ocular reproxalap in patients with allergic conjunctivitis, and phase 3 clinical trial plans based on recent feedback from the FDA. “The expanded results from our allergen
- Aerie Pharmaceuticals Announces the Appointment of David A. Hollander, MD, MBA, as Chief Research & Development Officerhttps://modernod.com/news/aerie-pharmaceuticals-announces-the-appointment-of-david-a-hollander-md-mba-as-chief-research-development-officer/2477056/Aerie Pharmaceuticals announced the appointment of David A. Hollander, MD, MBA, as Chief Research & Development Officer, an executive officer position reporting to Vicente Anido, Jr., PhD, Aerie’s Chairman and Chief Executive Officer. Dr. Hollander will commence his employment at Aerie on Nov
- New Combined Data from the Phase 2 and Phase 3 Teprotumumab Clinical Trials to be Presented during the American Thyroid Association Annual Meetinghttps://modernod.com/news/new-combined-data-from-the-phase-2-and-phase-3-teprotumumab-clinical-trials-to-be-presented-during-the-american-thyroid-association-annual-meeting/2477038/New pooled data from the phase 2 and phase 3 clinical trials of teprotumumab, an investigational medicine being developed by Horizon Therapeutics, will be presented during an oral plenary presentation at the 89th Annual Meeting of the American Thyroid Association (ATA) in Chicago on Oc
- Johnson & Johnson Vision to Showcase New Data and Interactive Experiences at 2019 American Academy of Optometry Annual Meetinghttps://modernod.com/news/johnson-johnson-vision-to-showcase-new-data-and-interactive-experiences-at-2019-american-academy-of-optometry-annual-meeting/2477026/Johnson & Johnson Vision will be sharing new science and clinical practice information to advance treatment paradigms and vision outcomes together with eye care professionals at the 2019 American Academy of Optometry Annual Meeting, held October 23 – 27 in Orlando, Florida. “We&#
- Aerpio Pharmaceuticals Announces Review of Strategic Alternativeshttps://modernod.com/news/aerpio-pharmaceuticals-announces-review-of-strategic-alternatives/2477023/Aerpio Pharmaceuticals announced that its Board of Directors has initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value from the company’s clinical assets and cash resources, which amounted to $48.2 million as of June 30, 2019. The Boar
- Aura Biosciences Announces Updated Phase 1b/2 Clinical Data for AU-011 Presented at AAOhttps://modernod.com/news/aura-biosciences-announces-updated-phase-1b-2-clinical-data-for-au-011-presented-at-aao/2477015/Aura Biosciences announced the presentation of updated clinical data from its ongoing phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, the company’s lead product candidate for the first line treatment of primary choroidal melanoma, at the American Academy of
- Alcon Announces Findings from IRIS Registry Analyses on Real-World Cataract Patients at AAOhttps://modernod.com/news/alcon-announces-findings-from-iris-registry-analyses-on-real-world-cataract-patients-at-aao/2477012/Alcon announced findings from the American Academy of Ophthalmology IRIS Registry (Intelligent Research in Sight) that support the clinical value of the AcrySof platform. The IRIS Registry was used to assess characteristics and complications of IOL implantation after cataract surgery, according t
- ReNeuron Presents Positive Clinical Data at the American Academy of Ophthalmology Annual Meetinghttps://modernod.com/news/reneuron-presents-positive-clinical-data-at-the-american-academy-of-ophthalmology-annual-meeting/2477009/ReNeuron Group has announced that positive efficacy data were presented during the weekend at the American Academy of Ophthalmology Annual Meeting (AAO) in San Francisco from the company’s phase 1/2a clinical trial of its hRPC stem cell therapy in retinitis
- Kodiak Sciences Announces Data from Ongoing Phase 1b Study of KSI-301 in Patients With Wet AMD, DME and RVOhttps://modernod.com/news/kodiak-sciences-announces-data-from-ongoing-phase-1b-study-of-ksi-301-in-patients-with-wet-amd-dme-and-rvo/2477003/Kodiak Sciences announced promising safety, efficacy and durability data from its ongoing phase 1b study of its investigational therapy KSI-301 in patients with treatment-naïve wet age-related macular degeneration (AMD), diabetic macular edema (DME) and retinal vein